Skip to content

US · ALVOW · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Alvotech (ALVOW) intrinsic value and stock valuation

$0.37as of 2026-09-18 · Mkt cap 2.88B

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alvotech DCF and intrinsic value

InvestorsCraft values ALVOW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ALVOW’s statements →

Alvotech Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Luxembourg, LU, LU alvotech.com

How the business is doing

Fiscal 2025–2019, USD

Revenue
$31.9T-42.1% 5y CAGRd
20252019
Net income
-$-209.88T
20252019
Free cash flow
-$-96.6T
20252019
Total equity
-$-867.24T
20252020

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2025–2019, USD
FYFYFYFYFY
Revenue$586.3T$489.7T$91.4T$83T$36.8T
Operating income$78.2T$69.6T-$-354.86T-$-346.44T-$-235.46T
Net income$27.9T-$-231.86T-$-551.73T-$-513.58T-$-101.5T
EPSd$100K-$-865.41K-$-2.43M-$-2.6M-$-3.25M
Operating cash flow-$-50.2T-$-236.84T-$-312.19T-$-312.39T-$-228.17T
Capital expenditure-$-64.47T-$-57T-$-46.47T-$-49T-$-40.63T
Free cash flow-$-114.67T-$-293.84T-$-358.66T-$-361.39T-$-268.8T
Total assets$1,487.1T$1,221.4T$950.1T$828.4T$598T
Total debt$1,449.1T$1,190.2T$1,075.5T$805.1T$523.1T
Net debt$1,276.8T$1,138.8T$1,064.3T$738.7T$505.5T
Total equity-$-284.49T-$-412.77T-$-932.49T-$-564.42T-$-135.61T
Cash and short-term investments$172.4T$51.4T$11.2T$66.4T$17.6T
Income statement
FYFYFYFYFY
Revenue$586.3T$489.7T$91.4T$83T$36.8T
Cost of revenue$235.6T$185.3T$160.9T$64.1T$0.00
Gross profit$350.8T$304.4T-$-69.42T$18.9T$36.8T
Research and development expenses$184.2T$171.3T$210.8T$180.6T$191T
Selling, general and administrative expenses$90.9T$61.5T$73T$186.7T$84.1T
Other expenses-$-2.58T$1.96T$1.57T-$-1.99T-$-2.91T
Operating expenses$272.6T$234.7T$285.4T$365.4T$272.2T
Cost and expenses$508.1T$420T$446.3T$429.5T$272.2T
Interest income$198.5T$4.62T$4.82T$912B$19B
Interest expense$149.2T$157.6T$134.8T$91.4T$113T
Depreciation and amortization$37.9T$31.3T$24.2T$20.4T$18.2T
Ebitda$323.4T-$-32.28T-$-493.67T-$-439.8T-$-18.03T
Operating income$78.2T$69.6T-$-354.86T-$-346.44T-$-235.46T
Total other income/expenses, net$58.1T-$-287.21T-$-296.19T-$-205.21T$86.3T
Income before tax$136.3T-$-217.56T-$-651.05T-$-551.65T-$-149.2T
Income tax expense$108.4T$14.3T-$-99.32T-$-38.07T-$-47.69T
Net income$27.9T-$-231.86T-$-551.73T-$-513.58T-$-101.5T
Weighted average shares outstanding$279.2T$267.9T$227.3T$197.7T$31.3T
Weighted average diluted shares outstanding$279.2T$267.9T$227.3T$197.7T$31.3T
Balance sheet
FYFYFYFYFY
Cash and short-term investments$172.4T$51.4T$11.2T$66.4T$17.6T
Net receivables$153.8T$251.7T$87.2T$71.4T$53.9T
Inventory$220.1T$127.9T$74.4T$71.5T$39.1T
Total current assets$574T$455T$194.8T$230.7T$119.8T
Property, plant and equipment, net$356.4T$409.7T$356.6T$268.1T$205.3T
Goodwill and intangible assets$94.7T$32T$31.1T$37.3T$33.9T
Long-term investments$122.9T$22.7T$18.5T$48.6T$55.3T
Total non-current assets$913.1T$766.4T$755.2T$597.7T$478.2T
Total assets$1,487.1T$1,221.4T$950.1T$828.4T$598T
Accounts payable$126.1T$67.1T$80.6T$49.2T$28.6T
Short-term debt$49T$42.2T$47.7T$25.1T$10.1T
Deferred revenue$30.4T$16T$59.2T$36.9T$29.7T
Total current liabilities$304.1T$193.4T$261T$167.3T$111.8T
Long-term debt$1,400.1T$1,148T$1,027.8T$780T$513T
Deferred revenue, non-current$5.5T$80.7T$73.3T$57T$44.8T
Total non-current liabilities$1,467.5T$1,440.8T$1,621.6T$1,225.6T$621.8T
Capital lease obligations$150.1T$121.7T$115.3T$40.5T$122.1T
Total liabilities$1,771.6T$1,634.2T$1,882.6T$1,392.9T$733.6T
Common stock$2.93T$2.83T$2.28T$2.13T$135B
Retained earnings-$-2,409.79T-$-2,437.71T-$-2,205.85T-$-1,654.11T-$-1,140.53T
Accumulated other comprehensive income (loss)$16.7T$15.1T$41.4T$29.1T$4.67T
Total equity-$-284.49T-$-412.77T-$-932.49T-$-564.42T-$-135.61T
Total investments$122.9T$22.7T$18.5T$48.6T$55.3T
Total debt$1,449.1T$1,190.2T$1,075.5T$805.1T$523.1T
Net debt$1,276.8T$1,138.8T$1,064.3T$738.7T$505.5T
Cash flow statement
FYFYFYFYFY
Net income$27.9T-$-231.86T-$-551.73T-$-513.58T-$-101.5T
Depreciation and amortization$37.9T$31.3T$24.2T$20.4T$18.2T
Stock-based compensation$17.4T$7.63T$18T$10.3T$0.00
Change in working capital-$-117.64T-$-288.64T$26.3T-$-47.89T-$-6.81T
Accounts receivable-$-6.33T-$-164.24T-$-24.83T-$-13.23T-$-13.53T
Inventory-$-90.13T-$-49.97T-$-11.3T-$-32.41T-$-29.41T
Accounts payable-$-21.18T$0.00$0.00$0.00$14.3T
Net cash provided by operating activities-$-50.2T-$-236.84T-$-312.19T-$-312.39T-$-228.17T
Investments in property, plant and equipment-$-64.47T-$-53.66T-$-33.23T-$-37.88T-$-20.46T
Acquisitions, net-$-14.04T$12T$0.00$0.00$0.00
Net cash used for investing activities-$-104.22T-$-18.87T-$-46.34T-$-63.54T-$-40.63T
Common stock issued$78.7T$150.5T$136.9T$9.83T$185.9T
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$270.8T$297.3T$301.3T$424.9T$254.8T
Net change in cash$120.9T$40.3T-$-55.27T$48.9T-$-14.13T
Cash at end of period$172.4T$51.4T$11.2T$66.4T$17.6T
Operating cash flow-$-50.2T-$-236.84T-$-312.19T-$-312.39T-$-228.17T
Capital expenditure-$-64.47T-$-57T-$-46.47T-$-49T-$-40.63T
Free cash flow-$-114.67T-$-293.84T-$-358.66T-$-361.39T-$-268.8T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alvotech

        Alvotech Holdings SA is an Icelandic enterprise that, operating via its subsidiary companies, undertakes the development and fabrication of biosimilar pharmaceuticals destined for international consumption.

        CEO
        Lisa Graver
        Employees
        1.46K
        Beta
        0.19

        Explore

        Frequently asked questions

        What is the intrinsic value of Alvotech (ALVOW)?

        InvestorsCraft does not currently publish an intrinsic value for ALVOW. How the IC value is calculated.

        Is ALVOW undervalued?

        InvestorsCraft does not publish an undervaluation signal for ALVOW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.